iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/34076491
Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 16;34(3):e0002821.
doi: 10.1128/CMR.00028-21. Epub 2021 Jun 2.

Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use

M P E Slack  1 , A W Cripps  1   2 , K Grimwood  1   2   3   4 , G A Mackenzie  5   6   7 , M Ulanova  8
Affiliations
Review

Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use

M P E Slack et al. Clin Microbiol Rev. .

Abstract

Haemophilus influenzae serotype b (Hib) was previously the most common cause of bacterial meningitis and an important etiologic agent of pneumonia in children aged <5 years. Its major virulence factor is the polyribosyl ribitol phosphate (PRP) polysaccharide capsule. In the 1980s, PRP-protein conjugate Hib vaccines were developed and are now included in almost all national immunization programs, achieving a sustained decline in invasive Hib infections. However, invasive Hib disease has not yet been eliminated in countries with low vaccine coverage, and sporadic outbreaks of Hib infection still occur occasionally in countries with high vaccine coverage. Over the past 2 decades, other capsulated serotypes have been recognized increasingly as causing invasive infections. H. influenzae serotype a (Hia) is now a major cause of invasive infection in Indigenous communities of North America, prompting a possible requirement for an Hia conjugate vaccine. H. influenzae serotypes e and f are now more common than serotype b in Europe. Significant year-to-year increases in nontypeable H. influenzae invasive infections have occurred in many regions of the world. Invasive H. influenzae infections are now seen predominantly in patients at the extremes of life and those with underlying comorbidities. This review provides a comprehensive and critical overview of the current global epidemiology of invasive H. influenzae infections in different geographic regions of the world. It discusses those now at risk of invasive Hib disease, describes the emergence of other severe invasive H. influenzae infections, and emphasizes the importance of long-term, comprehensive, clinical and microbiologic surveillance to monitor a vaccine's impact.

Keywords: Haemophilus influenzae; Hib; conjugate vaccine; epidemiology; immunization; nontypeable H. influenzae.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Posteroanterior chest radiograph of an 11-month-old infant showing right-sided pneumonia caused by H. influenzae type b (copyright 2020 Grant Mackenzie).
FIG 2
FIG 2
Cartoon illustrating Hib conjugate vaccine. Polyribosyl ribitol phosphate (PRP) [composed of repeating units of 5-d-ribitol-(1→1)-β-d-ribose-3-phosphate] covalently linked to a carrier protein (chemical structure kindly provided by Neni Nurainy, Biofarma, Indonesia).
FIG 3
FIG 3
The six designated World Health Organization regions.
FIG 4
FIG 4
Number of cases of invasive Haemophilus influenzae infections in England, 1990 to 2018, by serotype (unpublished data from Public Health England, with permission from Shamez Ladhani).
FIG 5
FIG 5
Number of cases of invasive Haemophilus influenzae infection, by serotype, reported to National Institute of Communicable Diseases (NICD), South Africa, 2006 to 2018 (from GERMS-SA Annual Reports, 2006 to 2018, with permission from Anne von Gottberg, NICD, Johannesburg, South Africa) (139, 227–237).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moxon ER. 1995. Haemophilus influenzae, p 2039–2050. In Mandell GL, Bennett JE, Dolin R (ed), Mandell, Douglas and Bennett's principles and practice of infectious disease, 4th ed, vol 2. Churchill Livingstone, New York, NY.
    1. Käyhty H, Peltola H, Karanko V, Mäkelä PH. 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147:1100. 10.1093/infdis/147.6.1100. - DOI - PubMed
    1. Käyhty H, Karanko V, Peltola H, Mäkelä PH. 1984. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 74:857–865. - PubMed
    1. Anderson P. 1984. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149:1034–1035. 10.1093/infdis/149.6.1034. - DOI - PubMed
    1. Peltola H. 2000. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13:302–317. 10.1128/CMR.13.2.302. - DOI - PMC - PubMed